Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases

Seminars in Hematology

Volumn 40, Issue 2, 2003, Pages 116-123

  Cohen, Jeffrey I ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIINFECTIVE AGENT; CELL PROTEIN; CORTICOSTEROID; GAMMA INTERFERON; HETEROPHILE ANTIBODY; PARACETAMOL; PREDNISOLONE; PREDNISONE; RITUXIMAB; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA;

ADOPTIVE IMMUNOTHERAPY; ADULTHOOD; AGE; ANTIBODY DETECTION; AUTOIMMUNE HEMOLYTIC ANEMIA; B LYMPHOCYTE; BENIGN TUMOR; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELLULAR IMMUNITY; CHILDHOOD; CLINICAL FEATURE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; DISEASE SEVERITY; EPSTEIN BARR VIRUS; FEVER; GENE MUTATION; GRAFT VERSUS HOST REACTION; HERPES VIRUS INFECTION; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOBLASTIC LYMPHOMA; INFANCY; INFECTIOUS MONONUCLEOSIS; LEUKOCYTE COUNT; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MIXED CELL LYMPHOMA; NEUROLOGIC DISEASE; NONHUMAN; ORGAN TRANSPLANTATION; PALLIATIVE THERAPY; PRIORITY JOURNAL; RECIPIENT; REVIEW; SYMPTOMATOLOGY; T LYMPHOCYTE; THROMBOCYTOPENIA; UNITED STATES; UPPER RESPIRATORY TRACT OBSTRUCTION; X CHROMOSOME LINKAGE; X LINKED LYMPHOPROLIFERATIVE DISEASE;

EID: 0037395736     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0037-1963(03)70003-1     Document Type: Review

References (69)

1. Andersson J: Clinical and immunological considerations in Epstein-Barr virus-associated diseases. Scand J Infect Dis 100:72-82, 1996 (suppl)
2. Baranski B, Armstrong G, Truman JT, et al: Epstein-Barr virus in the bone marrow of patients with aplastic anemia. Ann Intern Med 109:695-704, 1988
3. Bottino C, Falco M, Parolini S, et al: NTB-A, a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. J Exp Med 194:235-246, 2001
4. + T cells in acute infectious mononucleosis. Nat Med 2:906-911, 1996
5. + T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 187:1395- 1402, 1998
6. Coffey AJ, Brooksbank RA, Brandau O, et al: Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 20:129-135, 1998
7. Cohen Jl: Epstein-Barr virus infection. N Engl J Med. 343:481-492, 2000
8. Cohen Jl: Epstein-Barr virus infections, including infectious mononucleosis, in Braunwald E, Fauci AS, Kasper DL, et al (eds): Harrison's Principles of Internal Medicine (ed 15). New York, NY, McGraw Hill, 2001, pp 1109-1111
9. Cohen Jl: Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine 70:137-160, 1991
10. Comoli P, Labirio M, Basso S, et al: Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active viral replication. Blood 99:2592-2598, 2002
11. a. Crotty S, Kersh EN, Cannons J: SAP is required for generating long-term humoral immunity. Nature 421:282-287, 2003
12. Czar MJ, Kersh EN, Mijares LA, et al: Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP. Proc Natl Acad Sci USA 98:7449-7454, 2001
13. Davis CL, Wood BL, Sabath DE, et al: Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 66:1770-1779, 1998
14. Emanuel DJ, Lucas KG, Mallory GB, et al: Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation 63:1691-1694, 1997
15. Enberg RN, Eberle BJ, Williams RC: T and B cells in the peripheral blood during infectious mononucelosis. J Infect Dis 130:104-111, 1974
16. Epstein MA, Achong BG, Barr YM: Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1:702-703, 1964
17. Faye A, Quartier P, Reguerre Y, et al: Chimaeric anti-CD20 monoclonal antibody (rituximab) in posttransplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 115:112-118, 2001
18. Finch SC: Laboratory findings in infectious mononucleosis, in Carter RL, Penman HG (eds): Infectious Mononucleosis. Oxford, UK, Blackwell Scientific, 1969, pp 47-62
19. Glaser SL, Lin RJ, Stewart SL, et al: Epstein-Barr virus-associated Hodgkin's disease: Epidemiologic characteristics in international data. Int J Cancer 70:375-382, 1997
20. Gottschalk S, Heslop HE, Rooney CM: Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res 84:175-201, 2002
21. Green M, Kaufmann M, Wilson J, et al: Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation. Clin Infect Dis 25:1344-1349, 1997
22. Haque T, Taylor C, Wilkie GM, et al: Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein-Barr virus-specific cyototoxic T cells. Transplantation 72:1399-1402, 2001
23. Haynes BF, Schooley RT, Payling-Wright CR, et al: Emergence of supressor cells of immunoglobulin synthesis during acute Epstein-Barr virus-induced infectious mononucleosis. J Immunol 123:2095-2101, 1979
24. Hislop AD, Annels NE, Gudgeon NH, et al: Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 195:893-905, 2002
25. Horowitz CA, Moulds J, Henle W, et al: Cold agglutinins in infectious mononucleosis and heterophile-antibody-negative mononucleosis-like syndromes. Blood 50:195-202, 1977
26. Imashuku S, Hibi S, Ohara T, et al: Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunotherapy. Blood 93:1869-1874, 1999
27. Khanna R, Bell S, Sherritt M, et al: Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci USA 96:10391-10396, 1999
28. Khanna R, Tellam J, Duraiswamy J, et al: Immunotherapeutic strategies for EBV-associated malignancies. Trends Mol Med 7:270-276, 2001
29. Kikuta H, Sakiyama Y, Matsumoto S, et al: Fatal Epstein-Barr virus-associated hemophagocytic syndrome. Blood 82:3259-3264, 1993
30. Kovalchuk AL, Qi C-F, Torrey TA, et al: Burkitt lymphoma in the mouse. J Exp Med 192:1183-1190, 2000
31. Latour S, Gish G, Helgason CD, et al: Regulation of SLAM- mediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat Immunol 2:681-690, 2001
32. Lazarus KH, Baehner RL: Aplastic anemia complication infectious mononucleosis: A case report and review of the literature. Pediatrics 67:907-910, 1981
33. Levy M, Kelly JP, Kaufman DW, et al: Risk of agranulocytosis and aplastic anemia in relation to history of infectious mononucleosis: A report from the International Agranulocytosis and Aplastic Anemia Study. Ann Hematol 67:187-190, 1993
34. Malouf MA, Chhajed PN, Hopkins P, et al: Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant 21:547-554, 2002
35. McDiarmid SV, Jordan S, Lee GS, et al: Prevention and pre-emptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 66:1604-1611, 1998
36. Milpied N, Antoine C, Garnier JL, et al: Humanized anti-CD20 monoclonal antibody (rituximab) in B posttransplant lymphoproliferative disorders (B PTLDs): A retrospective analysis of 32 patients. Ann Oncol 10:5, 1999 (suppl 13, abstr)
37. Morra M, Howie D, Grande MS, et al: X-linked lymphoproliferative disease: A progressive immunodeficiency. Ann Rev Immunol 19:657-682, 2001
38. Mroczek EL, Weisenburger DD, Grierson HL, et al: Fatal infectious mononucleosis and virus associated hemopagocytic syndrome. Arch. Pathol Lab Med 11:530-535, 1987
39. Nakajima H, Cella M, Bouchon A, et al: Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur J Immunol 30:3309-3318, 2000
40. Nichols KE, Harkin DP, Levitz S, et al: Inactivatiing mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci USA 95:13765-13770, 1998
41. Nichols KE: X-linked lymphoproliferative disease: Genetics and biochemistry. Rev Immunogenet 2:256-266, 2000
42. Okano M, Gross TG: Epstein-Barr virus-associated hemophagocytic syndrome and fatal infectious mononucleosis. Am J Hematol 53:111-115, 1996
43. O'Reilly RJ, Small TN, Papadopoulos E, et al: Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 157:195-216, 1997
44. Pallesen G, Hamilton-Dutoit SJ, Rowe M, et al: Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 337:320-322, 1991
45. Paya CV, Fung JJ, Nalesnik MA, et al: Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplantation 68:1517-1525, 1999
46. Pelletier LL, Borel DM, Romig DA, et al: Disseminated intravascular coagulation and hepatic necrosis. Complications of infectious mononucleosis. JAMA 235:1144-1146, 1976
47. Pipp ML, Means ND, Sixbey JW, et al: Acute Epstein-Barr virus infection complicated by severe thrombocytopenia. Clin Infect Dis 15:1237-1239, 1997
48. Riddler SA, Breinig MC, McKnight JLC: Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant patients. Blood 84:972-984, 1994
49. Rooney CM, Smith CA, Ng YC, et al: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphomas in allogeneic transplant recipients. Blood 92:1549-1555, 1998
50. Sayos J, Wu C, Morra M, et al: The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 395:462-469, 1998
51. Schooley RT, Densen P, Harmon D, et al: Antineutrophil antibodies in infectious mononucleosis. Am J Med 76:85-90, 1984
52. Seemayer TA, Gross TG, Egeler RM, et al: X-linked lymphoproliferative disease: Twenty-five years after the discovery. Pediatr Res 38:471-478, 1995
53. Setsuda J, Teruya-Feldsztein J, Harris NL, et al: Interleukin-18, interferon-γ, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease. Am J Pathol 155:257-265, 1999
54. Socinski MA, Ershler WB, Tosato G, et al: Pure red cell aplasia associated with chronic Epstein-Barr virus infection: Evidence for T-cell mediated suppression of erythroid colony forming unit. J Lab Clin Med 104:995-1006, 1984
55. Starzl TE, Nalesnik MA, Porter KA, et al: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1:583-7, 1984
56. Sullivan JL: Hematologic consequences of Epstein-Barr virus infection. Hematol Oncol Clin North Am 1:397-417, 1987
57. Sumaya CV, Ench Y: Epstein-Barr virus infectious mononucleosis in children. I. Clinical and general laboratory findings. Pediatrics 75:1003-1010, 1985
58. Sumegi J, Huang D, Lanyi A, et al: Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 96:3118-3125, 2000
59. Swinnen LJ, Mullen GM, Carr TJ, et al: Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 86:3333-3340, 1995
60. Sylla BS, Murphy K, Cahir-McFarland, et al: The X-linked lymphoproliferative syndrome gene product SH2D1A associates with p62dok (Dok1) and activates NF-κB. Proc Natl Acad Sci USA 97:7470-7475, 2000
61. Taga K, Chretien J, Cherney B, et al: Interleukin-10 inhibits apoptotic cell death in infectious mononucleosis T cells. J Clin Invest 94:251-260, 1994
62. + T cells specific for EBV in healthy virus carriers. J Immunol 162:1827-1835, 1999
63. Tomkinson BE, Wagner DK, Nelson DL, et al: Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol 139:3802-3807, 1987
64. Torre D, Tambini R: Acyclovir for treatment of infectious mononucleosis: a meta-analysis. Scand J Infect Dis 31:543-547, 1999
65. Tosato G, Magrath I, Koski I, et al: Activation of suppressor T cells during Epstein-Barr virus-induced infectious mononucleosis. N Engl J Med 301:1133-1137, 1979
66. Tynell E, Aurelius E, Brandell A, et al: Acyclovir and prednisolone treatment of acute infectious mononucleosis: A multicenter, double blind, placebo-controlled study. J Infect Dis 174:324-331, 1996
67. Van Esser JWJ, Niesters HGM, van der Holt B, et al: Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 99:4364-4669, 2002
68. Whitelaw F, Brook MG, Kennedy N, et al: Haemolytic anaemia complicating Epstein-Barr virus infection. Br J Clin Pract 49:212-213, 1995
69. Wu C, Nguyen KB, Pien GC, et al: SAP controls T cell responses to virus and terminal differentiation of TH2 cells. Nat Immunol 2:410-414, 2001